Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide

Hyeon-Uk Jeong1
Mihwa Kwon2
Yongnam Lee3
Ji Seok Yoo3
Dae Hee Shin3
Im-Sook Song2
Hye Suk Lee1

1College of Pharmacy, The Catholic University of Korea, Bucheon 420-743, Korea; 2College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 702-701, Korea; 3Central R&D Institute, Yungjin Pharm Co., Ltd., Suwon 443-270, Korea

Abstract: We investigated the in vitro transport characteristics of catalposide in HEK293 cells overexpressing organic anion transporter 1 (OAT1), OAT3, organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic cation transporter 1 (OCT1), OCT2, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP). The transport mechanism of catalposide was investigated in HEK293 and LLC-PK1 cells overexpressing the relevant transporters. The uptake of catalposide was 319-, 13.6-, and 9.3-fold greater in HEK293 cells overexpressing OAT3, OATP1B1, and OATP1B3 transporters, respectively, than in HEK293 control cells. The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3). The concentration-dependent OAT3-mediated uptake of catalposide revealed the following kinetic parameters: Michaelis constant ($K_m$) = 41.5 μM, maximum uptake rate ($V_{max}$) = 46.2 pmol/minute, and intrinsic clearance ($CL_{int}$) = 1.11 μL/minute. OATP1B1- and OATP1B3-mediated catalposide uptake also showed concentration dependency, with low $CL_{int}$ values of 0.035 and 0.034 μL/minute, respectively. However, the OCT1, OCT2, OAT1, P-gp, and BCRP transporters were apparently not involved in the uptake of catalposide into cells. In addition, catalposide inhibited the transport activities of OAT3, OATP1B1, and OATP1B3 with half-maximal inhibitory concentration values of 83, 200, and 235 μM, respectively. However, catalposide did not significantly inhibit the transport activities of OCT1, OCT2, OAT1, P-gp, or BCRP. In conclusion, OAT3, OATP1B1, and OATP1B3 are major transporters that may regulate the pharmacokinetic properties and may cause herb–drug interactions of catalposide, although their clinical relevance awaits further evaluation.

Keywords: catalposide, drug transporters, herb–drug interaction, OAT3, OATP1B1, OATP1B3

Introduction

*Catalpa ovata* has been used as traditional herbal medicines for the treatment of inflammation, itching, and scabies. It contains iridoid and naphthoquinones, and catalposide is a bioactive iridoid glucoside isolated from *C. ovata* (Figure 1).1,2 Recently, catalposide was reported to be a novel natural ligand of peroxisome proliferation-activated receptor α (PPAR-α), which regulates hepatic lipid metabolism.3 In addition, it showed inhibitory effects on tumor necrosis factor-α, interleukin 1β (IL-1β), and IL-6 production and nuclear factor-κB activation in lipopolysaccharide-activated RAW 264.7 macrophages, as well as cytotoxic effects against oxidative damage caused by the induction of heme oxygenase-1.4,5 The effective concentration of catalposide required for the suppression of cytokines, antioxidative effect, and PPAR-α activation...
has been reported in the range of 0.2–4 μM in an in vitro cell system. Catalposide attenuated the increased expression of intestinal epithelial proinflammatory gene and reduced the severity of colitis induced by trinitrobenzene sulfonic acid in mice at a dose of 0.5 mg/kg. Administration of higher-dose catalposide (1–2.5 mg/kg) resulted in a similar therapeutic effect without histologic toxicity.

Ji et al investigated the pharmacokinetics of catalposide in rats after intravenous administration. Plasma concentration of catalposide showed biphase disposition with a terminal half-life of 19.3±9.5 minutes. It also showed a high distribution volume (2657.2±1396.9 mL/kg). In addition, systemic clearance of catalposide was 96.7±44.2 mL/minute/kg, and the renal and nonrenal clearance of catalposide was 8.47 and 88.2 mL/kg/minute, respectively. In the recovery of catalposide after intravenous administration (10 mg/kg), 9.9% was found in the urine. However, catalposide remained stable after a 3-hour incubation in rat and human plasma, as well as in the presence of NADPH in rat and human liver microsomes. These results, taken together, suggest catalposide is distributed rapidly into specific organs or the whole body and/or is subject to non-cytochrome P450 (non-CYP)-mediated metabolism, with subsequent excretion in the bile or urine. A significant amount of catalposide was excreted into the urine in its unchanged form (9.9% of the intravenous dose), suggesting a transport mechanism may be involved in its renal excretion. However, the metabolism and transport mechanism of catalposide and significance of drug metabolizing enzymes and transporters in the metabolism, distribution, and elimination need further investigation.

Recently, transporters have been suggested to be important in in vivo drug disposition, drug responses, and adverse drug reactions. In addition, information regarding drug transporters is increasing in drug labels and provides information for understanding the mechanisms of drug absorption, distribution, and elimination.

A long and continuous history of dietary use has demonstrated the safety of many herbs, and some herb-derived drugs are important therapeutics. However, there is a growing trend for the concurrent administration of herbal ingredients with drugs, which can cause serious herb–drug interactions (HDIs). For example, hyperforin, contained in St John’s wort, significantly reduces plasma concentrations of cyclosporine, amitriptyline, digoxin, warfarin, phenprocoumon, midazolam, tacrolimus, indinavir, and theophylline. Common herbal medicines, including ginseng (Panax ginseng), ginkgo (Ginkgo biloba), garlic (Allium sativum), and ginger (Zingiber officinale), have been reported to interact with drugs such as digoxin, warfarin, midazolam, cyclosporine, tacrolimus, irinotecan, amitriptyline, and indinavir. Among the underlying mechanisms for the most commonly reported HDIs, modulation of drug transporters is an important mechanism.

Thus, the purpose of this study was to evaluate the transport characteristics of catalposide and possible transporter-based catalposide–drug interactions, using HEK293 and LLC-PK1 cell systems overexpressing uptake and efflux transporters, such as organic anion transporter 1 (OAT1), OAT3, organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic cation transporter 1 (OCT1), OCT2, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP).

Materials and methods

Materials

[3H]Para-aminohippuric acid (PAH; 0.13 TBq/mmol), [3H]estrone-3-sulfate (ES; 2.12 TBq/mmol), [3H]estradiol-17β-d-glucuronide (EG; 2.22 TBq/mmol), [3H]digoxin (1.103 TBq/mmol), and [3H]methyl-4-phenylpyridinium (MPP+; 2.9 TBq/mmol) were purchased from Perkin Elmer Inc. (Boston, MA, USA). Catalposide, tetraethylammonium chloride, probenecid, rifampin, cyclosporin A (CsA), 4-methylumbelliferone, and nonessential amino acids were obtained from Sigma-Aldrich (St Louis, MO, USA). Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), poly-D-lysine-coated 24-well plates, and Hank’s balanced salt solution (HBSS) were purchased from Corning-Gentest (Tewksbury, MA, USA). Methanol and acetonitrile (high-performance liquid chromatography-grade) were from Burdick & Jackson Inc. (Muskegon, MI, USA). Sodium butyrate and fumitrogen C (FTC) were obtained from Merck.

Figure 1. Chemical structure of catalposide.
Millipore (Billerica, MA, USA). Other chemicals were of the highest quality available.

**Evaluation of catalposide as a substrate of OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, P-gp, and BCRP transporters**

HEK293 cells overexpressing OAT1, OAT3, OATP1B1, OATP1B3, OCT1, and OCT2 transporters were maintained in a humidified atmosphere of 5% CO₂ at 37°C, in DMEM supplemented with 10% FBS, and 5 mM nonessential amino acids. For the experiments, 4×10⁵ cells were seeded in poly-D-lysine-coated 24-well plates. After 24 hours, the growth medium was discarded and the attached cells were washed with HBSS and preincubated for 10 minutes in HBSS at 37°C.

The uptake of 10 μM catalposide was measured in the absence and presence of representative inhibitors (200 μM probenecid for OAT1 and OAT3, 100 μM rifampin for OATP1B1 and OATP1B3, and 10 mM tetracylammonium for OCT1 and OCT2) for 10 minutes at 37°C, or 5 minutes at 37°C for OATP1B1 and OATP1B3. The cells were then washed three times with 100 μL ice-cold HBSS immediately after placing the plates on ice. Subsequently, 300 μL 80% methanol containing internal standard (4-methylumbelliferone 10 ng/mL) was added to each sample well, and the cell plates were shaken gently for 20 minutes at room temperature. One hundred microliters of each sample was added to 100 μL methanol and centrifuged (13,000× g, 4 minutes, 4°C), and the supernatant was recovered and evaporated. The residue was dissolved in 50 μL 15% methanol, and an aliquot (7 μL) was analyzed using the liquid chromatography–high-resolution mass spectrometry.

LLC-PK1 cells overexpressing P-gp and BCRP transporters were grown in tissue culture flasks in DMEM supplemented with 20% FBS, 4 mM L-glutamine, 1% nonessential amino acids, and 1% penicillin-streptomycin. The cells were seeded onto filter membranes at a density of 5×10⁵ cells/well. Transepithelial electrical resistance values in the range of 300–650 Ω cm² were used in the transport experiment as a marker of the integrity of the cell monolayers. The apical-to-basal (A-to-B) transport of catalposide was measured by adding 0.5 mL HBSS containing 20 μM catalposide with or without 20 μM CsA for P-gp or 100 μM FTC for BCRP on the apical side and by adding 1.5 mL HBSS without catalposide on the basal side of the insert. The insert was transferred to a well containing fresh HBSS medium every 15 minutes for 1 hour. The basal-to-apical (B-to-A) transport of catalposide was measured by the addition of 1.5 mL of HBSS containing 20 μM catalposide with or without 20 μM CsA or 100 μM FTC on the basal side, and 0.5 mL of HBSS without catalposide on the apical side. The transport medium in the apical side was replaced with 0.4 mL fresh incubation medium every 15 minutes for 1 hour. One hundred fifty microliters B-to-A transport rate samples and 200 μL A-to-B transporter rate samples were added to 10 μL methanol containing the internal standard (4-methylumbelliferone 100 ng/mL) and 150 or 200 μL methanol, respectively. Subsequently, each sample was centrifuged (13,000× g, 4 minutes, 4°C), and the supernatant was recovered and evaporated. The residue was dissolved in 50 μL 30% methanol, and an aliquot (7 μL) was analyzed by liquid chromatography–high-resolution mass spectrometry.

To examine the concentration dependence of the uptake of catalposide in HEK293 cells overexpressing OAT3, OATP1B1, and OATP1B3 transporters, the cells were maintained at 37°C in a humidified atmosphere of 5% CO₂ in DMEM supplemented with 10% FBS and 5 mM nonessential amino acids. For the experiments, 4×10⁵ cells were seeded in poly-D-lysine-coated 24-well plates. After 24 hours, the growth medium was discarded and the attached cells were washed with HBSS and preincubated for 10 minutes in HBSS at 37°C. To examine the concentration dependence of the uptake of catalposide via OAT3, OATP1B1, and OATP1B3, the uptake of various concentrations of catalposide (2–500 μM) was measured for 10 minutes at 37°C for OAT3, and for 5 minutes at 37°C for OATP1B1 and OATP1B3.

To evaluate the effects of representative inhibitors on the uptake of catalposide in HEK293 cells transiently expressing OAT3, OATP1B1, and OATP1B3 transporters, the cells were maintained and seeded as described previously, and the uptake of 10 μM catalposide was measured in the absence and presence of various concentrations of representative inhibitors (1, 10, and 200 μM probenecid and 10, 100, and 1,000 μM cimetidine and furosemide for OAT3, and 0.1, 1, and 10 μM CsA; 10, 100, and 1,000 μM gemfibrozil; and 1, 10, and 100 μM rifampin for OATP1B1 and OATP1B3) for 10 minutes at 37°C for OAT3 and for 5 minutes at 37°C for OATP1B1 and OATP1B3.

**Analysis of catalposide**

For the quantification of catalposide, an Exactive Orbitrap mass spectrometer (Thermo Scientific, San Jose, CA, USA) coupled with an Accela ultraperformance liquid chromatography system was used. In the case of uptake transport studies, catalposide was eluted through a Halo C18 column (2.7 μm, 2.1 mm internal diameter×50 mm; Advanced Materials Technology, Wilmington, DE, USA) with a mobile phase consisting of 5% methanol in ammonium formate (1 mM at
pH 3.1; mobile phase A) and methanol (mobile phase B) at a flow rate of 0.5 mL/minute. The gradient mode was set as follows: 5% B for 2.7 minutes, 15% to 20% B in 4.3 minutes, 20% to 90% B in 0.5 minutes, 90% B for 3.0 minutes, 90% to 15% B in 0.5 minutes, and 15% B for 4 minutes.

In case of efflux transport studies and concentration dependency, quantification was performed using a Unison-C8 column (3.0 µm, 2.0 mm i.d. × 75 mm; Imtakt Corporation, Kyoto, Japan) with a gradient elution of 5% methanol in ammonium formate (1 mM at pH 3.1; mobile phase A) and methanol (mobile phase B) at a flow rate of 0.3 mL/minute: 30% B for 1.5 minutes, 30% to 95% B in 0.1 minutes, 95% B for 3.4 minutes, 95% to 30% B in 0.1 minutes, 30% B for 2.9 minutes at a flow rate of 0.4 mL/minute, 0.4 mL/minute to 0.3 mL/minute in 0.1 minutes, and 30% B for 0.4 minutes at a flow rate of 0.3 mL/minute. The column and autosampler temperatures were 40°C and 6°C, respectively. The mass spectrometer was equipped with an electrospary ionization (ESI) source and was operated in negative ion mode. The ESI source settings for the ionization of catalposide were as follows: capillary voltage, 3,000 V; vaporizer temperature, 400°C; capillary temperature, 330°C; sheath gas pressure, 50 psi; and auxiliary gas pressure, 15 psi. The accurate masses of the deprotonated molecular ions ([M-H]−) of catalposide and 4-methylumbelliferone were 481.13461 and 175.03952, respectively. Analytical data were processed using the Xcalibur software (Thermo Scientific).

Inhibitory effects of catalposide on transport activities of OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, P-gp, and BCRP

HEK293 cells overexpressing OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, P-gp, and BCRP were purchased from Corning-Gentest. The cells were maintained at 37°C in a humidified atmosphere of 5% CO₂ in DMEM supplemented with 10% FBS, 5 mM nonessential amino acids, and 100 U/mL penicillin-streptomycin. For the experiments, 10⁶ cells were seeded in 96-well plates. After 24 hours, the growth media were discarded and the attached cells were washed with HBSS and preincubated for 20 minutes in HBSS at 37°C. To examine the effects of catalposide on transporter activity, the uptake of 0.1 µM [3H]MPP⁺ for OCT1 and OCT2, 1 µM [3H]PAH for OAT1, 0.1 µM [3H]ES for OAT3 and OATP1B1, and 0.1 µM [3H]EG for OATP1B3 was measured in the presence of catalposide (0–100 µM for OAT1, OCT1, and OCT2 and 0–500 µM for OAT3, OATP1B1, and OATP1B3) for 10 minutes at 37°C. The cells were then washed three times with 100 µL ice-cold HBSS immediately after placing the plates on ice and lysed with 10% sodium dodecyl sulfate. The radioactivity of the probe substrate in the cells was measured using a liquid scintillation counter.

LLC-PK1-MDR1 (LLC-PK1 cells stably expressing P-gp; purchased from Corning-Gentest) and LLC-PK1-BCRP (LLC-PK1 cells stably expressing BCRP; obtained from Dr AH Schinkel, Netherlands Cancer Institute, Amsterdam, the Netherlands) cells were used for the comparison of the B-to-A transport rate of [3H]digoxin and [3H]ES in the absence and presence of catalposide. Briefly, the cells were seeded on filter inserts for 24-well Transwell plates at a density of 5×10⁵ cells and grown for 5 days. Cell monolayers with transepithelial electrical resistance in the range of 300–850 Ω cm² were used in the transport experiment. B-to-A transport was initiated by adding 0.8 mL HBSS containing [3H]digoxin or [3H]ES (0.1 µM each) and catalposide (1, 10, 50, and 100 µM) on the basal side and adding 0.3 mL of fresh HBSS on the apical side. Every 15 minutes, 0.2 mL HBSS sample on the apical side was removed and replaced with 0.2 mL fresh HBSS for 1 hour. The radioactivity of [3H]digoxin or [3H]ES in the HBSS was measured using a liquid scintillation counter.

Data analysis

The percentages of inhibition were calculated by the ratio of the amounts of catalposide in the presence and absence of inhibitors, and half-maximal inhibitory concentration (IC₅₀) values were calculated by using an inhibitory effect model \( V = E_{\text{max}} \left( 1 - \frac{[I]}{IC_{50} + [I]} \right) \), using WinNonlin (version 2.0; Pharsight, Mountain View, CA, USA). Here, \( E_{\text{max}} \) represents the maximum effect achieved by the system, \( [I] \) represents the concentration of an inhibitor, and \( IC_{50} \) represents the concentration of an inhibitor that is required for 50% inhibition. In the concentration-dependent uptake studies, the OAT3-, OATP1B1-, and OATP1B3-mediated transport of catalposide was calculated by subtracting the transport rates of the mock cells from those of the OAT3-, OATP1B1-, and OATP1B3-expressing HEK293 cells. Kinetic parameters for the OAT3-, OATP1B1-, and OATP1B3-mediated transport of catalposide were determined using the Hill equation \( \frac{V}{V_{\text{max}}} = \frac{S^n}{(K_m^n + S^n)} \) and the Enzyme Kinetics software (version 1.3; Systat Software Inc., San Jose, CA, USA). Here, \( V_{\text{max}} \) represents the maximum uptake rate, \( S \) represents the concentration of a substrate, \( n \) is the Hill coefficient, and \( K_m \) represents the concentration of a substrate that is required for 50% of \( V_{\text{max}} \). The statistical significance was assessed by Student’s \( t \)-test, using Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA).
Results
OAT3-, OATP1B1-, and OATP1B3-mediated transport of catalposide

We evaluated catalposide as a substrate of the OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, P-gp, and BCRP transporters. The functionality of these transporters was confirmed by the significantly greater uptake rate of the substrates in HEK293 cells expressing various transporters than that in HEK293 mock cells (ie, 25.0-fold increase in PAH uptake for OAT1; 18.9-fold increase in ES uptake for OAT3; 17.3-fold increase in ES uptake for OATP1B1; 15.0-fold increase in EG uptake for OATP1B3; 15.0-fold increase in MPP⁺ uptake for OCT1; and 17.8-fold increase in MPP⁺ uptake for OCT2). Moreover, transport activity of P-gp and BCRP was also confirmed by the net efflux ratios of representative substrate in LLC-PK1 cells overexpressing P-gp and BCRP transporters. Net efflux ratio was calculated by comparing the efflux ratio of substrate in LLC-PK1 cells overexpressing P-gp and BCRP with that in LLC-PK1-mock cells. The net efflux ratio of digoxin and ES was 5.7 and 4.6 in LLC-PK1-MDR1 and LLC-PK1-BCRP compared with LLC-PK1-mock cells, respectively.

The uptake of catalposide was 319-, 13.6-, and 9.3-fold increased in HEK293 cells overexpressing the OAT3, OATP1B1, and OATP1B3 transporters, respectively, compared with that in HEK293 mock cells. Moreover, the increased uptake rate of catalposide mediated by OAT3, OATP1B1, and OATP1B3 was decreased to basal levels in the presence of representative inhibitors, such as probenecid and rifampin (Table 1). However, the OCT1, OCT2, and OAT1 transporters were apparently not involved in the uptake of catalposide into cells. In addition, the net efflux ratios of catalposide were 0.92 in LLC-PK1 cells overexpressing P-gp and BCRP transporters, and they were not changed by the presence of representative inhibitors of P-gp and BCRP (CsA and FTC, respectively) in LLC-PK1-MDR1 or LLC-PK1-BCRP cells (Table 2). On the basis of these results, it can also be concluded that catalposide is not a substrate of the MDR1 or BCRP transporters.

We further evaluated OAT3-, OATP1B1-, and OATP1B3-mediated catalposide transport in the presence of representative inhibitors. Cimetidine, furosemide, and probenecid, representative inhibitors of OAT3, inhibited OAT3-mediated catalposide transport in a concentration-dependent manner.

### Table 1 Fold increases in the transporter-mediated uptake of catalposide

<table>
<thead>
<tr>
<th>Cells, transporters, and inhibitors</th>
<th>Transport rate, pmol/minute</th>
<th>Fold increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEK293-mock cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>For OAT1, OAT3</td>
<td>0.0443±0.0030</td>
<td>1.0</td>
</tr>
<tr>
<td>For OCT1, OCT2</td>
<td>0.0245±0.0009</td>
<td>1.0</td>
</tr>
<tr>
<td>For OATP1B1, OATP1B3</td>
<td>0.0372±0.0047</td>
<td>1.0</td>
</tr>
<tr>
<td>HEK293 cells overexpressing transporters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OAT1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.0413±0.0039</td>
<td>0.9</td>
</tr>
<tr>
<td>Probenecid 200 μM</td>
<td>0.0351±0.0026</td>
<td>0.8</td>
</tr>
<tr>
<td>OAT3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>14.1±0.21*</td>
<td>319</td>
</tr>
<tr>
<td>Probenecid 200 μM</td>
<td>0.101±0.0011†</td>
<td>2.3</td>
</tr>
<tr>
<td>OCT1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.0226±0.0013</td>
<td>0.9</td>
</tr>
<tr>
<td>TEA 10 mM</td>
<td>0.0260±0.0050</td>
<td>1.1</td>
</tr>
<tr>
<td>OCT2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.0273±0.0019</td>
<td>1.1</td>
</tr>
<tr>
<td>TEA 10 mM</td>
<td>0.0251±0.0039</td>
<td>1.0</td>
</tr>
<tr>
<td>OATP1B1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.505±0.081*</td>
<td>13.6</td>
</tr>
<tr>
<td>Rifampin 100 μM</td>
<td>0.0394±0.0022†</td>
<td>1.1</td>
</tr>
<tr>
<td>OATP1B3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.344±0.017*</td>
<td>9.3</td>
</tr>
<tr>
<td>Rifampin 100 μM</td>
<td>0.0382±0.0034‡</td>
<td>1.0</td>
</tr>
</tbody>
</table>

**Notes:** Transport rate was calculated by dividing the uptake of catalposide in HEK293-mock cells and HEK293 cells overexpressing transporters for 5 min or 10 min by the incubation time. Fold increases were calculated by comparing catalposide uptake in HEK293 cells overexpressing transporters with those in HEK293-mock cells. *P<0.01, significantly different compared with HEK293-mock cells. †P<0.01, significantly different compared with control group.

**Abbreviations:** OAT, organic anion transporter; OCT, organic cation transporter; OATP, organic anion transporting polypeptide; TEA, tetraethylammonium.
Similarly, CsA, gemfibrozil, and rifampin, representative inhibitors of OATP1B1 and OATP1B3, also showed inhibitory effects on both OATP1B1- and OATP1B3-mediated catalposide transport in a concentration-dependent manner (Figure 2B and C). These results suggest that catalposide is actively taken up into cells via the OAT3, OATP1B1, and OATP1B3 transporters.

To determine the kinetic parameters of concentration-dependent uptake of catalposide via OAT3, OATP1B1, and OATP1B3 transporters, the uptake of catalposide was

---

**Table 2** Efflux ratio of catalposide in the LLC-PK1-mock, LLC-PK1-MDR1, and LLC-PK1-BCRP cells

<table>
<thead>
<tr>
<th>Cells, transporters, and inhibitors</th>
<th>Transport rate, pmol/minute</th>
<th>Efflux ratio</th>
<th>Net efflux ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLC-PK1-mock cells</td>
<td>0.606±0.10</td>
<td>0.837±0.088</td>
<td>1.4</td>
</tr>
<tr>
<td>LLC-PK1 cells overexpressing transporters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-gp Control</td>
<td>0.281±0.020</td>
<td>0.359±0.014</td>
<td>1.3</td>
</tr>
<tr>
<td>CsA 20 μM</td>
<td>0.236±0.007</td>
<td>0.432±0.032</td>
<td>1.8</td>
</tr>
<tr>
<td>BCRP Control</td>
<td>0.827±0.15</td>
<td>1.05±0.12</td>
<td>1.3</td>
</tr>
<tr>
<td>FTC 100 μM</td>
<td>0.837±0.041</td>
<td>1.08±0.14</td>
<td>1.3</td>
</tr>
</tbody>
</table>

**Notes:** A-to-B transport rate was calculated by dividing the apical-to-basal transport of catalposide in LLC-PK1-mock cells and LLC-PK1 cells overexpressing transporters for 60 min by the incubation time. B-to-A transport rate was calculated by dividing the basal-to-apical transport of catalposide in LLC-PK1-mock cells and LLC-PK1 cells overexpressing transporters for 60 min by the incubation time. Efflux ratio was calculated by dividing the basal-to-apical transport rate of catalposide in LLC-PK1 cells overexpressing transporters by that in LLC-PK1-mock cells. Net efflux ratio was calculated by comparing the efflux ratio of catalposide in LLC-PK1 cells overexpressing transporters with that in LLC-PK1-mock cells.

**Abbreviations:** P-gp, P-glycoprotein; BCRP, breast cancer resistance protein; CsA, cyclosporin A; FTC, fumitrogen C.

---

**Figure 2** Effects of representative inhibitors on the uptake of catalposide in HEK293 cells expressing (A) organic anion transporter 3 (OAT3), (B) organic anion transporting polypeptide 1B1 (OATP1B1), and (C) OATP1B3 transporters.

**Notes:** Concentrations of 1, 10, and 200 μM probenecid and 10, 100, and 1,000 μM cimetidine and furosemide were used as inhibitors of OAT3. In addition, 0.1, 1, and 10 μM cyclosporin A; 10, 100, and 1,000 μM gemfibrozil; and 1, 10, 100 μM rifampin were used as inhibitors of OATP1B1 and OATP1B3 transporters. Bars represent the means ± standard deviation of three independent experiments. *P<0.01, significantly different compared with control group.
measured in HEK293 cells overexpressing OAT3, OATP1B1, and OATP1B3 transporters with various concentrations of catalposide (2–500 μM; Figure 3). The $K_m$, $V_{max}$, and intrinsic clearance ($Cl_{int}$) values of catalposide uptake in OAT3 were 41.5 μM, 46.2 pmol/minute, and 1.11 μL/minute, respectively. In the case of OATP1B1, $K_m$, $V_{max}$, and $Cl_{int}$ were 220.5 μM, 7.7 pmol/minute, and 0.035 μL/minute, respectively. For OATP1B3, $K_m$, $V_{max}$, and $Cl_{int}$ were 502 μM, 16.9 pmol/minute, and 0.034 μL/minute, respectively.

Inhibitory effect of catalposide on OAT3, OATP1B1, and OATP1B3 transport activity

The inhibitory effects of catalposide on eight major transporters were evaluated using HEK293 and LLC-PK1 cell systems overexpressing OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, P-gp, and BCRP transporters. Catalposide inhibited the transport activities of OAT3 with $IC_{50}$ of 83 μM. Inhibitory effect of catalposide on the transport activities of OATP1B1 and OATP1B3 was also observed, as evidenced by high $IC_{50}$ values of 200 and 235 μM, respectively (Figure 4). In contrast to these transporters, catalposide did not significantly inhibit transport activities of OCT1, OCT2, OAT1, P-gp, or BCRP in the concentration ranges tested (Figure 4).

Discussion

In this study, we comprehensively assessed the substrate specificity of catalposide with regard to clinically important drug transporters such as OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, P-gp, and BCRP, as well as the inhibitory effects of catalposide on these transporters. Among these eight transporters, cellular accumulation of catalposide was mediated by OAT3, OATP1B1, and OATP1B3 transporters, as evidenced by the 319-, 13.6-, and 9.3-fold increases in catalposide uptake in HEK293 cells overexpressing OAT3, OATP1B1, and OATP1B3 transporters.
OATP1B1, and OATP1B3, respectively, compared with that in HEK293 mock cells. We further confirmed the substrate specificity of catalposide by examining OAT3-, OATP1B1-, and OATP1B3-mediated catalposide uptake in the presence of representative inhibitors of these transporters. Cimetidine, furosemide, and probenecid were selected as inhibitors of OAT3, with IC\textsubscript{50} values of 92.4±10.9, 51.1±10.5, and 4.93±27.9 \mu M, respectively.\textsuperscript{17,18} On the basis of these IC\textsubscript{50} values, various concentrations of OAT3 inhibitors were applied to assess OAT3-mediated catalposide uptake. It was observed that 100 \mu M cimetidine and furosemide inhibited OAT3-mediated catalposide uptake by 70.4% and 98.3%, respectively, whereas

![Figure 4](https://i.imgur.com/3.png)
10 μM probenecid inhibited catalposide uptake by 84.5%. These differential inhibitory effects could be attributed to the different IC₅₀ values of the OAT3 inhibitors, and collectively, the results show that OAT3 is involved in the catalposide uptake process. Similarly, CsA, gemfibrozil, and rifampin were selected as inhibitors of OATP1B1 with IC₅₀ values of 1.88, 156.2, and 0.99 μM, respectively.³⁹,⁴⁰ CsA, gemfibrozil, and rifampin were also applied as inhibitors of OATP1B3, with IC₅₀ values of 0.20, ~200, and 0.65 μM, respectively.³⁹–⁴¹

Use of 1 μM CsA resulted in inhibition of OATP1B1- and OATP1B3-mediated catalposide uptake by 65.3% and 73.3%, respectively. Gemfibrozil and rifampin inhibited OATP1B1- and OATP1B3-mediated catalposide uptake in a similar manner. Consistent with these results, OATP1B1- and OATP1B3-mediated catalposide uptake showed concentration dependency (Figure 3). The Hill coefficients for OAT3, OATP1B1, and OATP1B3 were all close to 1, suggesting a reversible and competitive interaction between these transporters and catalposide, with 1:1 stoichiometry.²²,²³ The 𝐶𝑙ᵢₘ value for OAT3 was 31.8-fold and 32.7-fold greater than those for OATP1B1 and OATP1B3, respectively, which seems to be mainly attributable to the low 𝐾ₘ and high 𝑉ₘ₄ values compared with those for OATP1B1 and OATP1B3. Considering that OAT3 is expressed predominantly in the kidney and plays a role in the uptake of organic anionic drugs from the blood,²⁴,²⁵ OAT3 may contribute to the renal distribution and excretion of catalposide. Although the affinities of OATP1B1 and OATP1B3 were considerably lower than those of OAT3, OATP1B1, and OATP1B3, they may contribute to the hepatic distribution of this compound, based on their predominant expression in the liver.²⁶

OAT3, OATP1B1, and OATP1B3 transporters mediated renal and hepatic uptake of catalposide, which would be excreted via renal and biliary routes with or without coupling non-CYP mediated metabolism. Therefore, we first explored the involvement of P-gp and BCRP. From the results of Table 2, we concluded that these transporters were not involved in the excretion of catalposide. In spite of the lack of involvement of P-gp and BCRP in the transport of catalposide (Table 2), we should note the limitation of the use of specific inhibitors. We used CsA (25 μM) and FTC (100 μM) as P-gp and BCRP inhibitors, respectively. CsA inhibits not only P-gp but also other transporters such as OATP family transporters, multidrug resistance-associated protein 2 (MRP2), bile salt efflux pump, and Na⁺-taurocholate cotransporting polypeptide.⁴ Therefore, the inhibition of other transporters by the CsA treatment can compromise the involvement of P-gp and other transporters. However, as we used LLC-PK1-MDR1 cells that overexpress P-gp, the inhibition of other transporters by CsA might play a minor role in the efflux of catalposide in LLC-PK1-MDR1 cells, if any. Similarly, a high concentration of FTC more than 10 μM was reported to inhibit P-gp function, as well as BCRP activity, in Caco-2 cells.²⁷ However, BCRP inhibition by 100 μM FTC was performed in LLC-PK1-BCRP cells in this study; therefore, even though we measured a combined inhibitory effect of BCRP and P-gp on the catalposide efflux in our system, the contribution of P-gp might be negligible.

Because catalposide is an anionic weak acid, it can be speculated that MRP transporters may be involved in its membrane transport. MRP transporters are known to efflux organic anions as well as glucuronidated, sulfated, and glutathione-conjugated metabolites.²⁸,²⁹ Among the MRP isoforms, MRP2 is expressed at the canalicular membrane, whereas MRP3 and MRP4 are expressed at the sinusoidal membrane of hepatocytes.³⁰ Because approximately 90% of catalposide was cleared by nonrenal clearance, it is possible that MRPs may facilitate biliary excretion of catalposide and/or its metabolites. MRP2 and MRP4 are also expressed at the apical membrane of renal proximal tubule epithelial cells,³¹ suggesting these transporters may also play a role in clearing catalposide³² via the renal route. Therefore, an investigation into MRP-mediated efflux transport of catalposide and its metabolites requires careful examination.

Because therapeutics are increasingly being used as “poly pills,” HDIs between coadministered herbs and drugs should be considered carefully, and the mechanisms underlying such HDIs have been investigated. Drug transporters, alone or in combination with drug-metabolizing enzymes, have drawn much attention in HDIs because they regulate the absorption, distribution, and elimination of drugs.⁸,¹⁶,³⁰,³¹

It is recommended that clinically important transporters, such as OAT1, OAT3, OATP1B1, OATP1B3, OCT2, P-gp, and BCRP, be considered for screening during drug development.³ However, it should be noted that in vivo drug interactions can be predicted from in vitro inhibition studies, using the effective plasma concentration, unbound fraction, and IC₅₀ values of inhibitors. Thus, it is important to determine whether the in vitro inhibition of OAT3, OATP1B1, and OATP1B3 transport activities by catalposide is in fact relevant through in vivo and, ultimately, clinical studies of the pharmacokinetics and efficacy of catalposide.⁸,¹⁶ As a result, IC₅₀ values for the OAT3, OATP1B1, and OATP1B3 transporters were estimated to be 83, 200, and 253 μM, respectively (Figure 4). The effective concentration of catalposide required for anti-inflammatory effect and PPAR-α activation has been reported as about 0.2–4 μM in an in vitro cell system.¹³,⁵,⁶
Table 3 Summary of transport characteristics of catalposide

<table>
<thead>
<tr>
<th>Transporter</th>
<th>Function</th>
<th>Substrate</th>
<th>$K_m$ (µM)</th>
<th>Inhibitor</th>
<th>Half-maximal inhibitory concentration, µM</th>
</tr>
</thead>
<tbody>
<tr>
<td>OAT1</td>
<td>Influx</td>
<td>No</td>
<td>–</td>
<td>No</td>
<td>–</td>
</tr>
<tr>
<td>OAT3</td>
<td>Influx</td>
<td>Yes</td>
<td>41.5</td>
<td>Yes</td>
<td>83</td>
</tr>
<tr>
<td>OATP1B1</td>
<td>Influx</td>
<td>Yes</td>
<td>221</td>
<td>Yes</td>
<td>200</td>
</tr>
<tr>
<td>OATP1B3</td>
<td>Influx</td>
<td>Yes</td>
<td>502</td>
<td>Yes</td>
<td>235</td>
</tr>
<tr>
<td>OCT1</td>
<td>Influx</td>
<td>No</td>
<td>–</td>
<td>No</td>
<td>–</td>
</tr>
<tr>
<td>OCT2</td>
<td>Influx</td>
<td>No</td>
<td>–</td>
<td>No</td>
<td>–</td>
</tr>
<tr>
<td>P-gp</td>
<td>Efflux</td>
<td>No</td>
<td>–</td>
<td>No</td>
<td>–</td>
</tr>
<tr>
<td>BCRP</td>
<td>Efflux</td>
<td>No</td>
<td>–</td>
<td>No</td>
<td>–</td>
</tr>
</tbody>
</table>

Abbreviations: OAT, organic anion transporter; OATP, organic anion transporting polypeptide; OCT, organic cation transporter; P-gp, P-glycoprotein; BCRP, breast cancer resistance protein; $K_m$, Michaelis constant.

However, the effective plasma concentration of catalposide has not been determined yet in in vivo animal and human studies, and the probability of in vivo drug–drug interactions between catalposide and substrates for OAT3, OATP1B1, and OATP1B3 should be carefully evaluated.

On this theme, previous research articles on the involvement of organic anion transporters in HDIs, and in particular OAT3, OATP1B1, and OATP1B3, were published. For example, bioactive flavonol, icariin, potentially inhibited OATP2B1 and OATP1B3 activities. Bicalein and wogonin (major components of Scutellaria baicalensis) significantly inhibited transport activities of OATP1B3, OAT1, and OAT3 and so on.

In conclusion, a comprehensive evaluation of the transport mechanisms and transporter-mediated HDI of catalposide on eight major transporters was conducted across a wide range of catalposide concentrations using HEK293 and LLC-PK1 cell systems overexpressing the OCT1, OCT2, OAT1, OAT3, OATP1B1, OATP1B3, P-gp, and BCRP transporters (Table 3). Uptake of catalposide was increased greatly in HEK293 cells overexpressing OAT3, OATP1B1, and OATP1B3 transporters compared with that in mock cells. In addition, catalposide inhibited the transport activities of OAT3, OATP1B1, and OATP1B3, with IC₅₀ values of 83, 200, and 253 µM, respectively. These findings suggest that OAT3, OATP1B1, and OATP1B3 transporters may be important in the pharmacokinetics and HDI of catalposide, although further evaluation is needed regarding their contribution to its pharmacokinetics in vivo.

Acknowledgments

This work was supported by the Industrial Strategic Technology Development Program (Global Botanical Drug Development for the US Food and Drug Administration approval of US clinical trials, 10039303) funded by the Ministry of Trade, Industry and Energy (MI, Korea) and The Catholic University of Korea, 2012 (M-2012-B0002-00024).

Disclosure

The authors report no conflicts of interest in this work.

References


